Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1942951 | 0.92 | BACE1 (0.32) | BACE1 | |
| SCHEMBL16267007 | 0.92 | — | — | |
| SCHEMBL17685647 | 0.89 | C5AR1 (0.30) | — | |
| SCHEMBL1535723 | 0.84 | BACE1 (0.31) | BACE1 | |
| SCHEMBL16267109 | 0.83 | CRHR1 (0.31) | — | |
| SCHEMBL133552 | 0.83 | BACE1 (0.30) | BACE1 | |
| SCHEMBL16699727 | 0.83 | BACE1 (0.30) | BACE1 | |
| SCHEMBL15995694 | 0.82 | — | — | |
| SCHEMBL712813 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL29659309 | 0.79 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244632-A1 | THERMAL INSULATION | MATERIA, INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160107980-A1 | CROSS METATHESIS OF POLY-BRANCHED POLY-OLEFINS | MATERIA, INC. | 2016-04-21 | — | — | US | disclosed |
| EP-1968954-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-20080214526-A1 | Macrocyclic Compounds and Compositions Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
| EP-1838680-A2 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007077004-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006074940-A2 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107980-A1 | CROSS METATHESIS OF POLY-BRANCHED POLY-OLEFINS | COASY, SQLE, FDFT1 | BACE1 255/4885 |
| US-20080214526-A1 | Macrocyclic Compounds and Compositions Useful as Bace Inhibitors | BACE1, BACE2, APP | BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.